Author

Thomas M. Savage

Columbia UniversityORCID 0000-0002-6618-2973Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Cathy Lee MendelsohniD· 1 shared Dylan L. MariuzzaiD· 1 shared Fangda LiiD· 1 shared Kenia de los SantosiD· 1 shared Mathieu RouanneiD· 1 shared Nicholas ArpaiaiD· 1 shared Noah CheniD· 1 shared Rosa L. VincentiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Cathy Lee MendelsohnORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy

Mathieu Rouanne, Noah Chen, Dylan L. Mariuzza, Zaofeng Yang, Fangda Li, Kenia de los Santos, Thomas M. Savage, Rosa L. Vincent, Cathy Lee Mendelsohn, Tal Danino, Nicholas Arpaia

This study shows engineered E. coli expressing CXCL13 enhances bladder cancer immunotherapy when combined with PD-1 blockade by promoting tumor-specific antibody responses.

Science Translational Medicine · Jul 22, 2026Peer-reviewedImmunology